Subscribe

WuXi AppTec Co., Ltd. (603259.SS)

CNY127.51 +7.27 (+6.05%)
CN SHH Healthcare Medical - Diagnostics & Research
Address 288 Fute Zhong Road 200131
Shanghai, SH, CN
CEO Ge Li
Website wuxiapptec.com
IPO 2018-05-08
ISIN CNE1000031K4

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 2359.HK (HKD) Other OTC · WUXAY (USD) Other OTC · WUXIF (USD) Shanghai Stock Exchange · 603259.SS (CNY)
Description

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY127.51 +7.27 (+6.05%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
48M
Beta
0.49
Float Shares
1.82B
Free Float %
73.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.79% -1.36% -7.26% +3.66% +11.42% +12.09% +59.97% +52.78% -27.08% +668.53% +668.53%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
127.51
DCF (Unlevered) 72.76 -42.9%
DCF (Levered) 142.08 +11.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 93% Bullish
Rating 2025-11 Change
Strong Buy 4 0
Buy 21 0
Hold 2 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
9.06
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Diagnostics & Research: +7.9%
    +19.9% ★ Q1'26: +28.8% (vs Q1'25)
  • ✓
    EPS growth Medical - Diagnostics & Research: +30.8%
    +101.5% ★ Q1'26: +23.4% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +42.3% ★ Q1'26: +19.5% (vs Q1'25)
  • ✓
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +53.3% ★ Q1'26: +39.5% (vs Q1'25)
  • ✓
    ROIC Medical - Diagnostics & Research: +5.2%
    +42.3% ★ Q1'26: +32.9% (vs Q1'25)
  • ✗
    Share dilution Medical - Diagnostics & Research: 0.0%
    +0.5% Q1'26: +2.6% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    0.30× ★ Q1'26: 0.43× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.56) × ERP
WACC = 97% × Ke + 3% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 72.76 Current price: 127.51
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
16 Rev. Ana.
16 EPS Ana. 		Dec 2027
19 Rev. Ana.
15 EPS Ana. 		Dec 2028
15 Rev. Ana.
12 EPS Ana.
Revenue
9.61B
est: 9.54B (+0.8%)
12.87B
est: 12.57B (+2.4%)
16.54B
est: 16.54B (-0.1%)
22.90B
est: 22.80B (+0.5%)
39.35B
est: 39.24B (+0.3%)
38.68B
est: 38.71B (-0.1%)
37.92B
est: 39.19B (-3.2%)
45.46B
est: 44.87B (+1.3%)
53.29B
51.65B – 56.28B
+18.8% YoY
62.25B
58.68B – 70.94B
+16.8% YoY
71.47B
71.38B – 71.55B
+14.8% YoY
EBITDA
2.39B
est: 2.74B (-12.9%)
3.27B
est: 3.61B (-9.4%)
3.91B
est: 4.75B (-17.6%)
5.42B
est: 6.54B (-17.1%)
10.64B
est: 11.26B (-5.5%)
11.89B
est: 13.99B (-15.1%)
14.55B
est: 14.16B (+2.7%)
27.69B
est: 16.22B (+70.7%)
19.26B
18.67B – 20.34B
+18.8% YoY
22.50B
21.21B – 25.64B
+16.8% YoY
25.83B
25.80B – 25.86B
+14.8% YoY
EBIT
1.84B
est: 2.26B (-18.4%)
2.58B
est: 2.97B (-13.4%)
3.10B
est: 3.91B (-20.9%)
4.35B
est: 5.39B (-19.4%)
9.15B
est: 9.28B (-1.4%)
9.83B
est: 11.83B (-16.9%)
12.09B
est: 11.97B (+1.0%)
24.21B
est: 13.71B (+76.6%)
16.28B
15.78B – 17.20B
+18.8% YoY
19.02B
17.93B – 21.68B
+16.8% YoY
21.84B
21.81B – 21.86B
+14.8% YoY
Net Income
2.26B
est: 2.19B (+3.3%)
1.85B
est: 2.34B (-20.8%)
2.96B
est: 3.00B (-1.4%)
5.10B
est: 4.82B (+5.7%)
8.81B
est: 8.63B (+2.1%)
9.61B
est: 8.53B (+12.6%)
9.45B
est: 10.03B (-5.8%)
19.19B
est: 18.80B (+2.1%)
18.02B
14.86B – 20.79B
-4.2% YoY
20.73B
16.90B – 23.92B
+15.0% YoY
24.46B
21.63B – 27.94B
+18.0% YoY
SGA
496.75M
est: 305.47M (+62.6%)
625.78M
est: 402.66M (+55.4%)
627.09M
est: 529.79M (+18.4%)
915.45M
est: 730.09M (+25.4%)
1.12B
est: 1.26B (-11.2%)
1.09B
est: 1.10B (-1.0%)
969.71M
est: 1.12B (-13.3%)
930.63M
est: 1.28B (-27.3%)
1.52B
1.47B – 1.61B
+18.8% YoY
1.78B
1.67B – 2.02B
+16.8% YoY
2.04B
2.04B – 2.04B
+14.8% YoY
EPS
0.95
est: 0.75 (+25.8%)
0.68
est: 0.81 (-15.8%)
1.06
est: 1.04 (+2.3%)
1.75
est: 1.66 (+5.2%)
3.01
est: 2.98 (+1.1%)
3.27
est: 2.92 (+12.0%)
3.28
est: 3.32 (-1.3%)
6.72
est: 5.75 (+16.9%)
6.02
5.10 – 7.14
+4.7% YoY
7.06
5.80 – 8.21
+17.3% YoY
8.18
7.42 – 9.59
+15.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-28 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-27 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-26 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-25 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-22 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-21 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-20 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-19 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-18 A- 4/5 4/5 5/5 5/5 3/5 2/5 2/5
2026-05-15 A 4/5 4/5 5/5 5/5 3/5 3/5 2/5
2026-05-14 A 4/5 4/5 5/5 5/5 3/5 3/5 2/5
2026-05-13 A 4/5 4/5 5/5 5/5 3/5 3/5 2/5
2026-05-12 A 4/5 4/5 5/5 5/5 3/5 3/5 2/5
2026-05-11 A 4/5 4/5 5/5 5/5 3/5 3/5 2/5
2026-05-08 A 4/5 4/5 5/5 5/5 3/5 3/5 2/5
2026-05-07 A 4/5 4/5 5/5 5/5 3/5 3/5 2/5
2026-05-06 A 4/5 4/5 5/5 5/5 3/5 3/5 2/5
2026-04-30 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-29 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-28 A- 4/5 4/5 5/5 5/5 2/5 3/5 2/5
2026-04-27 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5
2026-04-24 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5
2026-04-23 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5
2026-04-22 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5
2026-04-21 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5
2026-04-20 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5
2026-04-17 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5
2026-04-16 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5
2026-04-15 A 4/5 4/5 5/5 5/5 2/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
17.63B
OE per share TTM
6.48
Owner's Yield
5.93%
Maintenance CapEx ratio
13.52%
Maint CapEx / Avg PPE
65.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
715.6K
Shares Outstanding
2.47B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ge Li Co-Founder, Executive Chairman, President & Chief Executive Officer 42M —
Minzhang Chen Co-CEO & Executive Director 17M —
Qing Yang Co-CEO & Executive Director 17M —
Zhaohui Zhang Chief Operating Officer of China, Executive Vice President & Executive Director 8M male
Ming Shi Senior Vice President & Chief Financial Officer — female
Howard Wu Senior Vice President of Legal Department & Human Resources Department — —
Ruijia Tang IR Director — male
Tao Guo Senior Vice President of RCS IPM — male
Youchu Wang Senior Vice President of API Early Phase Development — —
Feng Zhang Senior Vice President of API Manufacturing — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research